

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A23L 1/305, A61K 31/195, 38/02		A1	(11) International Publication Number: WO 97/16983 (43) International Publication Date: 15 May 1997 (15.05.97)		
(21) International Application Number: PCT/US96/17241		(81) Designated States: JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).			
(22) International Filing Date: 24 October 1996 (24.10.96)		Published <i>With international search report.</i>			
(30) Priority Data: 08/556,035 9 November 1995 (09.11.95) US 08/695,792 12 August 1996 (12.08.96) US					
(71) Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US/US); Suite 350, 900 Welch Road, Palo Alto, CA 94304-1850 (US).					
(72) Inventors: COOKE, John, P.; 4022 Ben Lomond Drive, Palo Alto, CA 94306 (US). DZAU, Victor, J.; 12101 Dawn Lane, Los Altos Hills, CA 94022 (US). GIBBONS, Gary, H.; 3212 Morris Drive, Palo Alto, CA 94303 (US). SCHWARZACHER, Sverin; 8 Cleland Place, Menlo Park, CA 94025 (US). LIM, Tai, T.; Block 1E, Gillman Heights Number 16-43, Singapore (SG). YEUNG, Alan, C.; 85 Sugar Hill Drive, Hillsborough, CA 94010 (US).					
(74) Agents: ROWLAND, Bertram, I. et al.; Flehr, Hohbach, Test, Albritton & Herbert, 4 Embarcadero Center, Suite 3400, San Francisco, CA 94111-4187 (US).					

(54) Title: ENHANCEMENT OF VASCULAR FUNCTION BY MODULATION OF ENDOGENOUS NITRIC OXIDE PRODUCTION OR ACTIVITY



(57) Abstract

Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host. Alternatively, or in combination, other compounds may be administered which provide for short term enhancement of nitric oxide, either directly or by physiological processes. An intramural process is provided for preventing restenosis by introducing precursor amino acid(s) through the balloon lumen (14) into the interior chamber (13) of the balloon (12). During inflation, the balloon (12) presses outwardly against the vessel wall (15) and the precursor amino acid(s) are introduced into the vessel wall (15).

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**ENHANCEMENT OF VASCULAR FUNCTION BY MODULATION OF
ENDOGENOUS NITRIC OXIDE PRODUCTION OR ACTIVITY**

INTRODUCTION

This invention was supported in part by the United States Government under Grant 1K07HC02660 (NHLBI). The 5 U.S. Government may have an interest in this application.

Technical Field

The field of this invention is the modulation of NO activity, which finds application in maintaining and 10 improving vascular function and thereby preventing or improving vascular degenerative diseases.

Background

Atherosclerosis and vascular thrombosis are a major 15 cause of morbidity and mortality, leading to coronary artery disease, myocardial infarction, and stroke. Atherosclerosis begins with an alteration in the endothelium, which lines the blood vessels. The endothelial alteration results in adherence of monocytes, 20 which penetrate the endothelial lining and take up residence in the subintimal space between the endothelium and the vascular smooth muscle of the blood vessels. The monocytes absorb increasing amounts of cholesterol (largely in the form of oxidized or modified low-density 25 lipoprotein) to form foam cells. Oxidized low-density lipoprotein (LDL) cholesterol alters the endothelium, and the underlying foam cells distort and eventually may even rupture through the endothelium.

Platelets adhere to the area of endothelial disruption and release a number of growth factors, including platelet derived growth factor (PDGF). PDGF, which is also released by foam cells and altered 5 endothelial cells, stimulates migration and proliferation of vascular smooth muscle cells into the lesion. These smooth muscle cells release extracellular matrix (collagen and elastin) and the lesion continues to expand.

Macrophages in the lesion elaborate proteases, and the 10 resulting cell damage creates a necrotic core filled with cellular debris and lipid. The lesion is then referred to as a "complex lesion." Rupture of this lesion can lead to thrombosis and occlusion of the blood vessel. In the case of a coronary artery, rupture of a complex lesion may 15 precipitate a myocardial infarction, whereas in the case of a carotid artery, stroke may ensue.

One of the treatments that cardiologists and other interventionalists employ to reopen a blood vessel which is narrowed by plaque is balloon angioplasty 20 (approximately 300,000 coronary and 100,000 peripheral angioplasties are performed annually). Although balloon angioplasty is successful in a high percentage of the cases in opening the vessel, it unfortunately denudes the endothelium and injures the vessel in the process. This 25 damage causes the migration and proliferation of vascular smooth muscle cells of the blood vessel into the area of injury to form a lesion, known as myointimal hyperplasia or restenosis. This new lesion leads to a recurrence of symptoms within three to six months after the angioplasty 30 in a significant proportion of patients (30-40%).

In atherosclerosis, thrombosis and restenosis there is also a loss of normal vascular function, such that vessels tend to constrict, rather than dilate. The excessive vasoconstriction of the vessel causes further 35 narrowing of the vessel lumen, limiting blood flow. This can cause symptoms such as angina (if a heart artery is

involved), or transient cerebral ischemia (i.e. a "small stroke", if a brain vessel is involved). This abnormal vascular function (excessive vasoconstriction or inadequate vasodilation) occurs in other disease states as well. Hypertension (high blood pressure) is caused by excessive vasoconstriction, as well as thickening, of the vessel wall, particularly in the smaller vessels of the circulation. This process may affect the lung vessels as well causing pulmonary (lung) hypertension. Other disorders known to be associated with excessive vasoconstriction, or inadequate vasodilation include transplant atherosclerosis, congestive heart failure, toxemia of pregnancy, Raynaud's phenomenon, Prinzmetal's angina (coronary vasospasm), cerebral vasospasm, hemolytic-uremia and impotence.

Because of their great prevalence and serious consequences, it is critically important to find therapies which can diminish the incidence of atherosclerosis, vascular thrombosis, restenosis, and these other disorders characterized by abnormality of vascular function and structure. Ideally, such therapies would inhibit the pathological vascular processes associated with these disorders, thereby providing prophylaxis, retarding the progression of the degenerative process, and restoring normal vasodilation.

As briefly summarized above, these pathological processes are extremely complex, involving a variety of different cells which undergo changes in their character, composition, and activity, as well as in the nature of the factors which they secrete and the receptors that are up- or down-regulated. A substance released by the endothelium, "endothelium derived relaxing factor" (EDRF), may play an important role in inhibiting these pathologic processes. EDRF is now known to be nitric oxide (NO) or a labile nitroso compound which liberates NO. (For purposes of the subject invention, unless otherwise indicated,

nitric oxide (NO) shall intend nitric oxide or the labile nitroso compound which liberates NO.) This substance relaxes vascular smooth muscle, inhibits platelet aggregation, inhibits mitogenesis and proliferation of 5 cultured vascular smooth muscle, and leukocyte adherence. Because NO is the most potent endogenous vasodilator, and because it is largely responsible for exercise-induced vasodilation in the conduit arteries, enhancement of NO synthesis could also improve exercise capacity in normal 10 individuals and those with vascular disease. NO may have other effects, either direct or indirect, on the various cells associated with vascular walls and degenerative diseases of the vessel.

15 Relevant Literature

Girerd et al. (1990) *Circulation Research* 67:1301-1308 report that intravenous administration of L-arginine potentiates endothelium-dependent relaxation in the hind limb of cholesterol-fed rabbits. The authors conclude 20 that synthesis of EDRF can be increased by L-arginine in hypercholesterolemia. Rossitch et al. (1991) *J. Clin. Invst.* 87:1295-1299 report that in vitro administration of L-arginine to basilar arteries of hypercholesterolemic rabbits reverses the impairment of endothelium-dependent 25 vasodilation and reduces vasoconstriction. They conclude that the abnormal vascular responses in hypercholesterolemic animals is due to a reversible reduction in intracellular arginine availability for metabolism to nitric oxide.

30 Creager et al. (1992) *J. Clin. Invest.* 90:1248-1253, report that intravenous administration of L-arginine improves endothelium-derived NO-dependent vasodilation in hypercholesterolemic patients.

Cooke et al., "Endothelial Dysfunction in 35 Hypercholesterolemia is Corrected by L-arginine," *Endothelial Mechanisms of Vasomotor Control*, eds.

Drexler, Zeiher, Bassenge, and Just; Steinkopff Verlag Darmstadt, 1991, pp. 173-181, review the results of the earlier references and suggest, "If the result of these investigations may be extrapolated, exogenous 5 administration of L-arginine (i.e., in the form of dietary supplements) might represent a therapeutic adjunct in the treatment and/or prevention of atherosclerosis".

10 Cooke (1990) *Current Opinion in Cardiology* 5:637-644 discusses the role of the endothelium in the atherosclerosis and restenosis, and the effect that these 15 disorders have on endothelial function.

15 Cooke (1992) *J. Clin. Invest.* 90:1168-1172, describe the effect of chronic administration of oral L-arginine in hypercholesterolemic animals on atherosclerosis. This is 20 the first demonstration that oral L-arginine supplements can improve the release of NO from the vessel wall. The increase in NO release from the vessel wall was associated with a striking reduction in atherosclerosis in hypercholesterolemic animals. This is the first evidence 25 to support the hypothesis that increasing NO production by the vessel wall inhibits the development of atherosclerosis.

25 Cooke and Tsao (1992) *Current Opinion in Cardiology* 7:799-804 describe the mechanism of the progression of atherosclerosis and suggest that inhibition of nitric oxide may disturb vascular homeostasis and contribute to 30 atherogenesis.

30 Cooke and Santosa (1993) In: *Steroid Hormones and Dysfunctional Bleeding*, AAAS Press, review the activities of EDRF in a variety of roles and suggest that 35 reversibility of endothelial dysfunction may be affected by the stage of atherosclerosis. They conclude that EDRF is a potent vasodilator, plays a key role in modulating conduit and resistance vessel tone, has important effects on cell growth and interactions of circulatory blood cells with a vessel wall, and that disturbances of EDRF activity

may initiate or contribute to septic shock, hypertension, vasospasm, toxemia and atherosclerosis.

Fitzpatrick et al., *American Journal of Physiology* 265 (Heart Circ. Physiol. 34):H774-H778, 1993 report that 5 wine and other grape products may have endothelium-dependent vasorelaxing activity in vitro.

Wang et al. (1994) *J. Am. Coll. Cardiol.* 23:452-458, report that oral administration of arginine prevents atherosclerosis in the coronary arteries of 10 hypercholesterolemic rabbits.

Drexler et al. (1994) *Circulation* 89:1615-1623 describe the effect of intravenous arginine upon coronary vascular tone. This was the first evidence that 15 intravenous arginine could restore normal NO-dependent vasodilation in the coronary arteries of patients with cardiac transplants, Tsao et al. (1994) *Circulation* 89:2176-2182 demonstrates that oral administration of arginine to hypercholesterolemic rabbits enhances the release of nitric oxide by the vessel wall, and inhibits 20 monocytes from sticking to the vessel.

Tsao et al. (1994) *J. Arterioscl. Thromb.* 14:1529-1533 reveals that oral arginine administration to hypercholesterolemic rabbits inhibits platelet aggregation (blood clotting). Platelet aggregation plays an important 25 role in causing vascular thrombosis in vascular degenerative disorders.

Von de Leyen et al. (1995) *PNAS USA*, show that the gene encoding nitric oxide synthase (the enzyme that produces NO) can be inserted into the carotid artery of 30 the rat. This causes the rat carotid artery to make more NO, and thereby enhances vasodilation and inhibits thickening of the vessel wall after balloon angioplasty.

Noruse et al. (1994) *Arterioscler. Thromb.* 14:746-752, report that oral administration of an antagonist of 35 NO production accelerates atherogenesis in hypercholesterolemic rabbits.

Cayette et al. (1994) *Arterioscler. Thromb.* **14**:753-759, also report that oral administration of an antagonist of NO production accelerates plaque development in hypercholesterolemic rabbits.

5 Other references which refer to activities attributed to NO or its precursor include: Pohl and Busse (1989) *Circ. Res.* **65**:1798-1803; Radomski et al. (1987) *Br. J. Pharmacol.* **92**:181-187; Stamler et al. (1989) *Circ. Res.* **65**:789-795; anti-platelet activity); Garg and Hassid (1989) *J. Clin. Invest.* **83**:1774-1777; Weidinger et al. (1990) *Circulation* **81**:1667-1679; NO activity in relation to vascular smooth muscle growth); Ross (1986) *N. Engl. J. Med.* **314**:488-500; Bath et al. (1991) *Arterioscler. Thromb.* **11**:254-260; Kubes et al. (1991) *Proc. Natl. Acad. Sci. USA* **89**:6348-6352; Lefer et al. (1990) In: *Endothelium-Derived Contracting Factors*. Basel, S. Karger, pp.190-197; NO activity in relation to leukocyte adhesion and migration); Heistad et al. (1984) *Circ. Res.* **43**:711-718; Rossitch et al. (1991) *J. Clin. Invest.* **87**:1295-1299; Yamamoto et al. (1988) *ibid* **81**:1752-1758; Andrews et al. (1987) *Nature* **327**:237-239; Tomita et al. (1990) *Circ. Res.* **66**:18-27; Kugiyama et al. (1990) *Nature* **344**:160-162; Mitchell et al. (1992) *J. Vasc. Res.* **29**:169 (abst.); Minor et al. (1990) *J. Clin. Invest.* **86**:2109-2116; NO activity in relation to hypercholesterolemia); Tanner et al. (1991) *Circulation* **83**:2012-2020; Kuo et al. (1992) *Circ. Res.* **70**:f465-476; Drexler et al. (1991) *Lancet* **338**:1546-1550; Schuschke et al. (1994) *Int. J. of Microcircu: Clin. and Exper.* **14**(4):204-211; Yao et al. (1992) *Circulation* **86**:1302-1309; Higashi et al. (1995) *Hypertension* **25**(4 Pt 2):898-902; Kharitonov et al. (1995) *Clin. Sci.* **88**(2):135-139; Smulders et al. (1994) *Clin. Sci.* **87**(1):37-43; Bode-boger et al. (1994) *Clin. Sci.* **87**(3):303-310; Bode-Boger et al. (1994) *Clin. Sci.*; Randall et al. (1994) *Clin. Sci.* **87**(1):53-59; Dubois-Rande et al. (1992) *J. Card. Pharm.* **20** Suppl. **12**:S211-3; Otsuji et al. (1995) *Am. Heart J.*

129(6): 1094-1100; Nakanishi et al. (1992) *Am. J. of Physio.* 263(6 Pt 2):H1650-8; Kuo et al. (1992) *Circ. Research* 70(3): 465-476; Tanner et al. (1991) *Circulation* 83(6):2012-2020; Meng et al. (1995) *J. Am. Col. Card.* 5 25(1):269-275; Lefer and Ma (1993) *Arterioscl. and Thromb.* 13(6):771-776; McNamara et al. (1993) *Biochem. and Biophys. Res. Comm.* 193(1):291-296; Tarry and Makhoul (1994) *Arter. and Thromb.* 14(6):983-943; Davies et al. (1994) *Surgery* 116(3):557-568; and Raij (1994) *Kidney* 10 *Institute* 45:775-781.

SUMMARY OF THE INVENTION

Methods are provided for improving vascular function and structure, particularly modulating vascular 15 relaxation, cellular adhesion, infiltration and proliferation by modulating the level of nitric oxide or active precursor at a physiological site. The methods find use in preventing the degradation of vascular function, particularly as involved with the occurrence of 20 atherosclerosis, restenosis, thrombosis, hypertension, impotence, and other disorders characterized by reduced or inadequate vasodilation. The enhancement of endogenous nitric oxide or secondary messenger availability at a physiological site improves vascular relaxation and 25 thereby relieves symptoms due to inadequate blood flow (such as angina) and can counteract inappropriate elevation of blood pressure. The enhancement of endogenous nitric oxide also inhibits initiation and the progression of atherosclerosis, restenosis, vascular 30 hypertrophy or hyperplasia and thrombosis. This is due to the fact that nitric oxide is not only a potent modulator, but can also inhibit platelets and white blood cells from adhering to the vessel wall. As a prophylaxis or treatment for vascular function deterioration, 35 particularly in atherosclerotic susceptible hosts, the agent is chronically administered at an effective dosage.

For restenosis, the agent may be administered for a limited period since this pathological process generally abates 3-6 months after the vascular injury (i.e. angioplasty or atherectomy). Oral administration of 5 L-lysine, precursors to L-lysine, e.g. oligopeptides or polypeptides comprising L-lysine, or proteins comprising high levels of L-lysine, by itself or in combination with L-arginine, particularly further supplemented with GRAS substances which enhance the effectiveness of the active 10 agents, as a dietary supplement, will increase NO elaboration and thereby diminish the effects of atherogenesis. Other techniques to enhance NO or secondary messenger availability may be utilized such as increasing the availability of NO synthase, for example, 15 as a result of enhanced expression of NO synthase in the vessel wall, particularly at the lesion site, release of NO from the vessel wall or reduction of degradation of NO or the secondary messenger, cyclic guanosine monophosphate ("cGMP").

20

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a bar diagram of histomorphometric studies of the effect of L-arginine on atherosclerotic plaque in hypercholesterolemic animals. (See Ex. 1)

25 Figure 2 is a nephelometric scan of the effect of L-arginine diet supplement on platelet reactivity as evidenced by platelet aggregation initiated by adenosine diphosphate. (See Ex. 2) A) aggregation of platelets from hypercholesterolemic rabbit; B) reduced aggregation of 30 platelets from hypercholesterolemic rabbit treated with L-arginine; C) antagonism of NO synthase by LNMMMA reverses the beneficial effect of L-arginine.

Figure 3 is a bar diagram comparing the effect of L-arginine diet supplement on cell binding to aortic 35 endothelium of hypercholesterolemic animals. (See Ex. 4)

Figure 4. Lesion surface area of thoracic aortae from all arginine treated hypercholesterolemic animals (ARG, weeks 14-23) is reduced in comparison to that of hypercholesterolemic animals receiving vehicle (CHOL, 5 weeks 14-23). (See Ex. 5)

Figure 5. Macrophage accumulation in iliac arteries 4 weeks following balloon injury. (Macrophage infiltration into the vessel wall initiates and accelerates plaque formation). Data is expressed as a 10 percent of the vessel that contain macrophages. Balloon injury in hypercholesterolemic rabbits (CHOL) results in a marked increase in arterial macrophage accumulation compared with injured iliac arteries from rabbits on normal chow (CONT). Macrophage accumulation in iliac 15 arteries from hypercholesterolemic rabbits receiving L-arginine (ARG) is significantly reduced compared to the CHOL group. (*; p<0.01, ARG v. CHOL). This study revealed that oral arginine treatment markedly reduced the infiltration of monocytes/macrophages into the vessel 20 wall, explaining in part the effect of arginine to inhibit plaque formation. (See Ex. 6)

Figure 6. Stimulation of cultured endothelial cells with fluid flow causes them to secrete nitric oxide. Flow-induced secretion of nitric oxide decreases 25 endothelial adhesiveness induced by oxidized LDL cholesterol (oxLDL; 30 µg/ml). Exposure of human aortic endothelial cells to oxLDL increased the ex vivo binding of monocytes when compared to Control. In comparison to cells not exposed to flow (static), previous exposure to 30 flow inhibited the monocyte adhesion induced by oxLDL. These effects of flow were blocked by NO synthase inhibitors and mimicked by NO donors (PAPA-NO) or cyclic GMP (cGMP). Bars represent mean ± SEM. *p<0.05; **p<0.01. (See Ex. 8)

35 Figure 7 is a bar diagram of morphometric measurements of intimal lesion thickening two weeks after

a balloon angioplasty in animals treated with a plasmid construct containing the gene for NO synthase (INJ+NOS) in comparison to control vector (INJ+CV) or untreated injured vessels (INJ). (See Ex. 11)

5 Figure 8 is a histogram showing the effect of local intraluminal administration of arginine on restenosis. Hypercholesterolemic rabbits had balloon angioplasty of the iliac artery. Immediately thereafter some animals received an infusion of arginine directly into the vessel
10 by means of a catheter designed to apply high local concentrations of arginine to the vessel. Two to four weeks later, vessels were removed from the animals, and examined microscopically. Thickening of the vessel wall (internal thickening or "restenosis") was reduced in the
15 animals treated with intraluminal infusion of arginine (ARG) in comparison to those treated with vehicle. (See Ex. 12)

Figure 9 is a set of dose-response curves showing the effect of chronic lysine administration on endothelium dependent vasodilation in hypercholesterolemic rabbits. Chronic oral administration of lysine (for ten weeks) improved NO-mediated vasodilation; this improvement in NO activity was also associated with a marked reduction in plaque area. Chronic administration of lysine was just as effective as arginine in restoring vascular function and structure. (See Ex. 14)

Figure 10 is a scatter-diagram illustrating the relationship between the level of blood LDL-cholesterol and monocyte binding. Monocytes were isolated from the
30 blood of humans with normal or elevated cholesterol levels. The binding of these monocytes to endothelial cells in culture was observed. Monocytes from individuals with high cholesterol levels have a greater adhesiveness for endothelial cells. This monocyte-endothelial cell
35 interaction in vivo is the first step in the development of atherosclerotic plaque. (See Ex. 15)

Figure 11 is a bar diagram showing the adhesiveness of monocytes obtained from subjects with normal cholesterol levels (CONT) and those from hypercholesterolemic (HC) humans, before, during, and 5 after treatment with arginine (the NO precursor). Prior to initiating arginine (Arg) or placebo (plac) treatment, monocytes from hypercholesterolemic individuals have a greater tendency to bind to endothelial cells *ex vivo* (baseline). After 2 weeks of arginine treatment monocytes 10 from these hypercholesterolemic individuals have a significantly reduced adhesiveness and are no different from those of the normal subjects. At this point arginine therapy was discontinued and there was a washout (4 weeks). At this time point, monocytes from the patients 15 previously treated with arginine now have increased adhesiveness, off of the arginine treatment. (See Ex. 15)

Figure 12 is a bar diagram which shows that monocytes from individuals with elevated cholesterol (CHOL) have greater adhesiveness for endothelial cells. However, 20 after treatment with sodium nitroprusside (CHOL + SNP), the adhesiveness of these monocytes is normalized. SNP is an NO donor. (See Ex. 15)

Figure 13 is a set of histograms showing aggregation of platelets obtained in hypercholesterolemic humans (hc), 25 and individuals with normal cholesterol levels (nc). Platelet aggregation *ex vivo* in response to adenosine diphosphate (ADP) is increased in hc individuals in comparison to normal individuals. After 2 weeks of treatment with oral L-arginine, platelet aggregation is 30 attenuated in the hypercholesterolemic individuals, while an even greater effect of the treatment is seen at four weeks. (See Ex. 16)

Figure 14 is a bar graph showing increases in coronary blood flow in response to intracoronary infusions 35 of acetylcholine (ACH) before and after intravenous infusion of L-arginine (30 g), in patients with transplant

atherosclerosis. Acetylcholine stimulates the release of NO from the vessel wall causing vasodilation and increased blood flow. There is improved NO-dependent vasodilation after L-arginine administration. (See Ex. 18)

5 Figure 15 is a fragmentary view, partially in section, of a drug delivery apparatus for use in the subject invention positioned in a blood vessel with the dilatation balloon in its inflated state and containing a solution of an NO precursor.

10

DESCRIPTION OF SPECIFIC EMBODIMENTS

In accordance with the subject invention, vascular function is maintained or its deterioration inhibited or retarded by enhancing the level or activity of endogenous 15 nitric oxide. By enhancing the level or activity of endogenous nitric oxide, common vascular degenerative diseases such as atherosclerosis, restenosis, hypertension, vasospasm, impotence, angina, and vascular thrombosis, can be treated prophylactically and/or 20 therapeutically. The enhanced level or activity of nitric oxide (which is intended to include any precursor of nitric oxide which results in such enhanced level) can be achieved by modulating the activity, synthesis or 25 concentration of any of the components associated with the formation of nitric oxide in the nitric oxide synthetic pathway, or inhibiting the rate of degradation of nitric oxide, its precursors, or the secondary messengers 30 associated with the relaxation signal. In referring to the enhanced level or activity, the term "effect" will be used to encompass the two situations. The enhanced effect 35 of nitric oxide may be a result of oral or intravenous administration to the patient of a precursor in the metabolic pathway to the production of nitric oxide, particularly an amino acid (such as L-lysine, by itself or in combination with L-arginine (L-lysine, by itself or in combination with L-arginine, will be referred to as the

"amino acid(s)" or "NO precursor amino acid(s)}, polypeptides comprising these amino acids, and the like), providing an enzyme in the metabolic pathway to NO, particularly NO synthase, by introduction of the gene for 5 NO synthase under conditions for integration of the gene into the endothelial or other cells and expression of the gene, or by directly adding an enzyme associated with the production of nitric oxide. The enhanced level of nitric oxide may also result from administration of an agent to 10 protect the NO from degradation, such as an oxidant, reductant or superoxide dismutase. Alternatively, the agent may serve to enhance the bioavailability or effectiveness of the primary active agent, such as L-lysine or L-arginine. The agent, individually or in 15 combination, will be administered in a form of other than a natural food source, such as meat or plants as natural protein sources, fruits or products derived therefrom. When the amino acid(s) is the agent, the agent is supplied as a dietary supplement to enhance the normal daily dosage 20 of the amino acid and not as the primary source of the amino acid. Usually, the enhancement will be at least 25%, more usually at least 50% and may be 100% or more, preferably at least about 75%.

One approach is to employ L-lysine, as an individual 25 amino acid, or in combination with L-arginine, or as a precursor to L-lysine, e. g. a monomer or a polypeptide, as a dietary supplement. The amino acid(s) are administered as any physiologically acceptable salt, such as the hydrochloride salt, glutamate salt, etc. They can 30 also be administered as a peptide (e.g., poly-L-lysine, poly-L-arginine, or combinations thereof) so as to increase plasma levels of the NO precursor. Oligopeptides of particular interest include oligopeptides of from 2 to 30, usually 2 to 20, preferably 2 to 10 amino acids, 35 having at least 10 mol % of L-lysine, usually at least about 25 mol %, more usually at least about 50 mol % of L-

lysine, generally having a total of at least about 50 mol % of L-lysine and L-arginine, preferably at least about 75 mol % of L-lysine and L-arginine, more preferably having at least about 95 mol % of L-lysine and L-arginine.

5 The oligopeptides can be modified by being ligated to other compounds, which can enhance absorption from the gut, provide for enhancement of NO synthesis or stability, e.g. reducing agents and antioxidants, and the like.

Naturally occurring sources include protamine or

10 other naturally occurring NO precursor amino acid(s) containing protein, which is high in L-lysine or both of the indicated amino acids, e.g. greater than about 40%, preferably greater than about 50%. The amount of the L-lysine present will provide at least 25%, more usually

15 at least about 50%, of the therapeutic dosage desired for affecting the pathways associated with atherosclerosis and restenosis. As indicated, L-lysine may provide 100% of the therapeutic dosage, but desirably a combination of L-lysine and L-arginine will be used.

20 The administration of L-lysine, other convenient NO precursor, or other agent which enhances NO availability, would be in accordance with a predetermined regimen, which would be at least once weekly and over an extended period of time, generally at least one month, more usually at

25 least three months, and as a chronic treatment, could last for one year or more, including the life of the host. The dosage administered will depend upon the frequency of the administration, the blood level desired, other concurrent therapeutic treatments, the severity of the condition,

30 whether the treatment is for prophylaxis or therapy, the age of the patient, the natural level of NO in the patient, and the like. Desirably, the amount of the NO precursor amino acid(s) (K and R) or biologically equivalent compound which is used would generally provide

35 a plasma level in the range of about 0.15 to 30mM. The oral administration of K and R can be achieved by

providing K and R, other NO precursor, or NO enhancing agent as a pill, powder, capsule, liquid solution or dispersion, particularly aqueous, or the like. Various carriers and excipients may find use in formulating the NO precursor, such as lactose, terra alba, sucrose, gelatin, aqueous media, physiologically acceptable oils, e.g. peanut oil, and the like. Usually, if daily, the administration of K and R for a human host as a dietary supplement will be about 1 to 12g per day. If used as the sole source of the amino acids, the administration will be from about 5 to 20g per day.

Furthermore, other agents can be added to the oral formulation of the amino acids or polypeptides to enhance their absorption, and/or to enhance the activity of NO synthase, e.g. B₆ (50-250 mg/d), folate (0.4-10 mg per daily dose), B₁₂ (0.5-1 mg/d) or calcium (250-1000 mg per daily dose). Furthermore, agents known to protect NO from degradation, such as antioxidants (e.g. cysteine or N-acetyl cysteine 200-1000 mg/d Vitamin C (250-2000 mg daily dose), (coenzyme Q 25-90 mg daily dose, glutathione 50-250 mg daily dose), Vitamin E (200-1000 I.U. daily dose), or β-carotene (10-25,000 I.U. daily dose) or other naturally occurring plant antioxidants such as tocopherols, phenolic compounds, thiols, and ubiquinones can be added to the oral or intravenous formulations of the NO precursor amino acid(s) or peptides containing the NO precursor amino acid(s). Alternatively, one may include the active agent in a nutritional supplement, where other additives may include vitamins, amino acids other than the NO precursor amino acid(s), or the like, where the subject active agent will be at least 10 weight %, more usually at least about 25 weight % of the active ingredients.

The administration of the NO precursor amino acid(s) or its physiologic equivalent in supporting NO can be administered prophylactically to improve vascular function, serving to enhance vasodilation and to inhibit

atherogenesis or restenosis, or therapeutically after atherogenesis has been initiated. Thus, for example, a patient who is to undergo balloon angioplasty can have a regimen of the NO precursor amino acid(s) administered 5 substantially prior to the balloon angioplasty, preferably at least about a week or substantially longer. Alternatively, in a patient, the administration of NO precursor amino acid(s) can begin at any time. Conveniently, the amino acid composition can be 10 administered by incorporating the appropriate dose in a prepared food. Types of foods include gelatins, ice creams, cereals, candies, sugar substitutes, soft drinks, and the like. Of particular interest is the incorporation of NO precursor amino acid(s) as a supplement in a food, 15 such as a health bar, e.g. granola, other grains, fruit bars, such as a date bar, fig bar, apricot bar, or the like. The amount of NO precursor amino acid(s) or the equivalent would be about 1 - 25 g per dosage or bar, preferably about 2 - 15 g.

20 Methods and devices are provided for the treatment of pathologies associated with vascular injury, particularly in relation to angioplasty and atherectomy. Of particular interest is the injury referred to as restenosis, which results from the migration and 25 proliferation of vascular smooth muscle cells into the intima of the vessel as well as accretions associated with the atherosclerosis.

Instead of oral administration of the NO precursor amino acid(s), intravascular administration can be 30 employed, particularly where more rapid enhancement of the nitric oxide level in the vascular system is desired (i.e. as with acute thrombosis of a critical vessel), so that combinations of oral and parenteral administrations can be employed in accordance with the needs of the patient. 35 Furthermore, parenteral administration can allow for the administration of compounds which would not readily be

transported across the mucosa from the gastrointestinal tract into the vascular system.

In a particular application for intramural treatment to prevent restenosis, either L-lysine or L-arginine may 5 be used, individually, or in combination, as well as their biological equivalents, by themselves or in conjunction with other non-amino acid factors, described herein. The method provides introducing into the vessel walls at the site of injury an NO precursor, which results in the 10 enhancement of NO production in the cells at the site of injury. Various delivery systems may be employed which result in the NO forming agent infusing into the vessel wall, and being available to the cells for NO production. Devices which may be employed include drug delivery 15 balloons, e.g. porous, sonophoretic, and iontophoretic balloons, as exemplified by the devices depicted in WO92/11895, WO95/05866 and WO96/08286, as well as such commercial devices as Dispatch® (Scimed). See also Santoian et al., *Cath. Cardiov. Diag.* (1993) 30:348-354; 20 Muller et al., *J. Am. Coll. Cardiol.* (1992) 20:460-466; and Ortiz et al., *Circulation* (1994) 89:1518-1522. The NO precursor agent is introduced in a delivery balloon for transport by a catheter to the site of injury. The balloon may then be expanded under pressure driving the 25 agent from the balloon into the surrounding vessel wall. The amount of agent which is employed may vary depending upon the nature of the agent, the region to be treated, and the loss of the agent from the region. The infusion of the agent is maintained for sufficient time to ensure 30 that the cells and extracellular matrix in the injury region are exposed to the agent, so as to enhance the production of NO by these cells.

A physiologically acceptable medium will be employed, normally an aqueous medium, which may be deionized water, 35 saline, phosphate buffered saline, etc. The amount of the active NO precursor agent will vary depending upon the

particular agent employed, the other additives present, etc. Generally, as exemplified by L-arginine, at least about 50 mg will be present, and not more than about 5 g, usually at least about 100 mg, and not more than about 2 5 g, frequently at least about 500 mg. The concentration may be varied widely, generally ranging from about 20-500, more usually from about 50-250 g/l.

The time for the treatment will usually be at least about 2 minutes, and not more than about 0.5 hour, 10 generally ranging from about 5-15 minutes. The rate of introduction will generally range from about 0.05-5 ml/min, depending upon all of the other factors.

The subject methodology is employed with hosts who have suffered vascular injury, as caused by angioplasty 15 and atherectomies. The time for the administration of the NO precursor agent may be varied widely, providing a single administration or multiple administrations over a relatively short time period in relation to the time of injury. Generally, treatment may be before, concurrently 20 or after the injury, usually within 2 weeks of the injury, if before, and not more than about 8 weeks, usually not more than about 6 weeks, preferably in the range of 0-6 weeks (where 0 intends concurrently or shortly after the prior procedure, within 6 hours).

25 For the most part, the patients will be suffering from various conditions associated with narrowed vessels, particularly hypercholesterolemia, diabetes, tobacco use and hypertension. Thus, one will normally be dealing with vessels which are narrowed to varying degrees as a result 30 of the accumulation of plaque at the vessel wall.

It is found that with one treatment of the NO 35 precursor agent at or about the time of the injury, before or shortly thereafter, one can observe enhanced vascular NO production and reduced intimal thickening, so as to substantially reduce the potential for restenosis.

As indicated, various delivery devices may be employed for the delivery of the active agent. Figure 15 illustrates the drug delivery apparatus with the balloon 12 in its inflated state and within an arterial vessel in 5 which the vessel walls are indicated by the reference numeral 15. During percutaneous transluminal coronary angioplasty ("PCTA") procedures, the guide wire 10 is first inserted into the selected artery to a point past the stenotic lesion. The dilatation catheter including 10 the catheter body 11 and the balloon 12 is then advanced along the guide wire 10 to the desired position in the arterial system in which the balloon portion 12 traverses or crosses the stenotic lesion. The balloon 12 is then inflated by introducing the NO precursor solution through 15 the balloon lumen 14 into the interior chamber 13 of the balloon 12. During inflation, the outer surfaces of the balloon 12 press outwardly against the inner surfaces of the vessel wall 15 to expand or dilate the vessel in the area of the stenotic lesion, thus performing the 20 angioplasty portion of the method as well as the intramural introduction of the NO precursor into the vessel wall.

The porous balloon may be made from any of the conventional materials used for this purpose. These 25 include cellulose acetate, polyvinyl chloride, polysulfone, polyacrylonitrile, polyurethanes, natural and synthetic elastomers, polyolefins, polyesters, fluoropolymers, etc. Usually the film thickness will be in the range of about 10 \AA to 1 μ , with a nominal pore size 30 of about 0.05 to 1 μ .

Alternatively, a local drug delivery system may be employed where the agent is delivered to the vessel wall by channels that are on the exterior surface of the balloon. The balloon is placed into the diseased vessel 35 segment as described above. The balloon is then inflated in the usual manner (using saline, usually containing a

contrast agent), placing the channels (on the surface of the balloon) in contact with the vessel wall. The NO precursor solution is then infused under pressure into the channels. Perforations in the channels allow the solution 5 to exit and jet into the vessel wall under pressure to enhance intramural delivery.

Alternatively, a local drug delivery system may be employed where the agent is delivered to the vessel wall by channels that are on the exterior surface of the 10 balloon. The balloon is placed into the diseased vessel segment as described above. The balloon is then inflated in the usual manner (using saline, usually containing a contrast agent), placing the channels (on the surface of the balloon) in contact with the vessel wall. The NO 15 precursor solution is then infused under pressure into the channels. Perforations in the channels allow the solution to exit and jet into the vessel wall under pressure to enhance intramural delivery.

For oral or intravascular administration, one can 20 provide NO precursor amino acid(s), by itself or in a polypeptide, or its physiological equivalent in supporting NO, together with antioxidants or scavengers of oxygen-derived free radicals (such as sulphhydryl containing compounds) or compounds that prevent the production of 25 oxygen-derived free radicals (such as superoxide dismutase), as it is known that oxygen-derived free radicals (such as superoxide anion) can inactivate nitric oxide. In addition, one can administer cofactors required 30 for NO synthase activity, such as calcium or folate. The amounts of each of these co-agents can be determined empirically, using the assays in the experimental section 35 to determine NO activity.

The various cofactors that may be used with the NO precursors will vary in amount in relation to the amount 35 of NO precursor and the effectiveness of the cofactor, particularly for oral administration. Generally, the

cofactors may be present in amounts that would provide daily doses of folate (0.4-10 mg), B₆ (50-250 mg), B₁₂ (0.5-1 mg) and/or calcium (250-1000 mg). Usually, where the amount of the NO precursor is greater than about 2g, 5 it may be administered periodically during the day, being administered 2 to 4 times daily. For the most part, the cofactors will be GRAS substances and will be able to be taken at high dosages without adverse effects on the recipient host.

10 The subject compositions will be for the most part administered orally and the dosage may take a variety of forms. The dosage may be tablets, pill, capsules, powders, solutions, dispersions, bars, ice creams, gelatins, and the like, formulated with physiologically 15 acceptable carriers, and optionally stabilizers, colorants, flavoring agents, excipients, tabletting additives, and the like. Depending upon the mode of administration, the amount of active agent may be up to about 25g. For formulations as dietary supplements, 20 individual dosages will generally range from about 0.5 to 5g, more usually from about 1 to 3g of the NO precursor.

Alternatively, one can enhance, either in conjunction with the enhancement of precursors to nitric oxides or independently, components of the nitric oxide metabolic 25 pathway. For example, one can enhance the amount of nitric oxide synthase present in the vessel wall, particularly at the site of lesions. This can be done by local administration to the lesion site or systemically into the vascular system. The synthase can be 30 administered using liposomes, slow release particles, or in the form of a depot, e.g. in collagen, hyaluronic acid, biocompatible gels, vascular stents, or other means, which will provide the desired concentration of the NO synthase at the lesion site.

35 Instead of providing for the enhancement of NO at the physiological site of interest, one can choose to extend

the lifetime of the signal transduced as a result of the presence of nitric oxide. Since cGMP is produced intracellularly as a result of a nitric oxide induced signal, employing agents which result in the production of or extending the lifetime of cGMP can be employed. Illustrative agents include cGMP phosphodiesterase inhibitors or agents which increase the amount of guanylate cyclase.

Alternatively, cells can be genetically engineered to provide for constitutive or inducible expression of one or more genes, which will provide for the desired relaxation response, by expressing NO synthase, or other enzyme or protein which is secreted and acts extracellularly. Thus, expression vectors (viral or plasmid) can be prepared which contain the appropriate gene(s) and which can be introduced into host cells which will then produce high concentrations of nitric oxide or other intermediate in the relaxation pathway. These cells can be introduced at the lesion site or at another site in the host, where the expression will induce the appropriate response as to relaxation, proliferation, etc. The NO synthase or cells expressing the NO synthase can be present as depots by encapsulation and positioning at the site of interest. For example, porous stents can be produced which encapsulate the enzyme or cells to protect the enzyme from degradation or being washed away.

Cultured cells can be transfected with expression vectors containing the NO synthase or other gene ex-vivo and then introduced into the vessel wall, using various intra-arterial or intra-venous catheter delivery systems. Alternatively, techniques of in vivo gene transfer can be employed to transfect vascular cells within the intact vessel in vivo. The gene(s) can be expressed at high constitutive levels or can be linked to an inducible promoter (which can have tissue specificity) to allow for regulation of expression.

DNA constructs are prepared, where the appropriate gene, e.g. a NO synthase gene, is joined to an appropriate promoter, either with its native termination region or a different termination region, which can provide for 5 enhanced stability of the messenger RNA. Constitutive promoters of particular interest will come from viruses, such as Simian virus, papilloma virus, adenovirus, HIV, Rous sarcoma virus, cytomegalovirus or the like, where the promoters include promoters for early or late genes, or 10 long terminal repeats. Endogenous promoters can include the β -actin promoter, or cell-type specific promoters.

A construct is prepared in accordance with conventional techniques, the various DNA fragments being introduced into an appropriate plasmid or viral vector, 15 normally a vector capable of replication in a bacterial and/or eucaryotic host. Normally, the vector will include a marker, which allows for selection of cells carrying the vector, e.g. antibiotic resistance. The vector will normally also include an origin which is functional in the 20 host for replication. Other functional elements can also be present in the vector.

Once the vector has been prepared and replicated, it can then be used for introduction into host cells. The plasmid vector construct can be further modified by being 25 joined to viral elements which allow for ease of transfection, can provide a marker for selection, e.g. antibiotic resistance, or other functional elements. Introduction of the plasmid vector construct into the host cells can be achieved by calcium phosphate precipitated 30 DNA, transfection, electroporation, fusion, lipofection, viral capsid-mediated transfer, or the like. Alternatively, the expression construct within viral vectors can be introduced by standard infection 35 techniques. For somatic cell gene therapy, autologous cells will generally be employed, although in some instances allogeneic cells or recombinantly modified cells

can be employed. Usually the cells employed for genetic modification will be mature endothelial or vascular smooth muscle cells. Occasionally, the cells employed for genetic modification will be progenitor cells, 5 particularly early progenitor cells. For example, myoblasts can be employed for muscle cells or hematopoietic stem cells or high proliferative potential cells can be employed for lymphoid and/or myelomonocytic cells.

10 Depending upon the nature of the cells, they can be injected into tissue of the same or different cellular nature, they can be injected into the vascular system, where they may remain as mobile cells or home to a particular site (i.e. the lesion). For the NO synthase 15 gene, the number of cells which are administered will depend upon the nature of the cells, the level of production of the NO synthase, the desired level of NO synthase in the host vascular system, at the lesion site, or the like, whether the enhanced level of NO synthase is 20 the only treatment or is used in conjunction with other components of the nitric oxide synthetic pathway, and the like. Therefore, the particular number of cells to be employed will be determined empirically in accordance with the requirements of the particular patient.

25 These cells can also be introduced into the circulation by first growing them on the surface of standard vascular graft material (i.e. Dacron or polytetrafluoroethylene grafts) or other synthetic vascular conduits or vascular bioprostheses.

30 Alternatively, one can use viral vectors, which are capable of infecting cells *in vivo*, such as adenovirus or retroviruses. In this case, the viral vector containing the NO synthase gene or other gene involved with the relaxation pathway will be administered directly to the 35 site of interest, where it will enter into a number of cells and become integrated into the cell genome. Thus,

one can titer the desired level of nitric oxide synthase which is secreted or other protein which is expressed, by providing for one or more administrations of the virus, thus incrementally increasing the amount of synthase which 5 is secreted or other protein which is produced.

Alternatively, one can use modified liposomes as a vehicle for endovascular administration of the vector containing the NO synthase or other gene. One such modified liposome technique involves mixing the liposomes 10 with the vector containing NO synthase. Once the gene expression construct-containing vector is incorporated into the liposome, the liposomes are coated with a protein (e.g. the viral coat protein of the Hemagglutinating Virus of Japan) that increases the affinity of the liposome for 15 the vessel wall.

In some situations, the NO synthase or other gene in the relaxation pathway can be co-transfected with an artificial gene encoding an lysine and/or arginine rich polypeptide susceptible to proteolytic cleavage as an 20 intracellular source of L-lysine and/or L-arginine. In other situations, the NO synthase or other gene can be co-transfected with the superoxide dismutase gene, so as to inhibit the degradation of the nitric oxide.

In some situations, acute treatment may be involved, 25 requiring one or a few administrations. This will normally be associated with compounds which can act as nitric oxide precursors and are other than naturally occurring compounds or are compounds which can be added with naturally occurring compounds to enhance the rate of 30 formation of nitric oxide. Thus, one can provide for acute administration of NO precursor amino acid(s) and superoxide dismutase to increase the nitric oxide concentration over a restricted period of time. These 35 administrations can be independent of or in conjunction with long term regimens.

The following examples are offered by way of illustration and not by way of limitation.

EXPERIMENTAL

5 **Example 1. Anti-atherogenic effects of oral arginine:**

study design: (See, Cooke et al., 1992, *supra*) Male New Zealand white rabbits (n=49) were assigned to one of three treatment groups: 10 were fed with normal rabbit 10 chow for ten weeks (Control); 19 received chow enriched with 1% cholesterol (Chol); and 20 received a 1% cholesterol diet supplemented with 2.25% L-arginine hydrochloride in the drinking water (Arg.). Following ten weeks of the dietary intervention, animals were lightly 15 sedated and the central ear artery cannulated for measurement of intra-arterial blood pressure, followed by collection of blood samples for serum chemistries and plasma arginine. Subsequently the animals were sacrificed and the left main coronary artery and the thoracic aorta 20 were harvested for studies of vascular reactivity and histomorphometry. In some animals, blood was collected for studies of platelet and monocyte reactivity.

Results: Biochemical and physiological measurements. Hypercholesterolemic animals maintained on oral L-arginine 25 supplementation (Arg) experienced a twofold elevation in plasma arginine levels in comparison to animals on a normal (Control) or 1% cholesterol (Chol) diet alone; the elevation in plasma arginine was maintained throughout the course of the study. Serum cholesterol measurements were 30 elevated equally in both groups receiving the 1% cholesterol diet [50±6 vs. 1629±422 vs. 1852±356 mg/dl respectively for Control (=10), Chol (=13), and Arg (=14)]. There were no significant differences in hemodynamic measurements between groups.

35 **Organ chamber studies of isolated vessels:** For NO-independent responses, there were no differences between

the treatment groups in maximal response or sensitivity to norepinephrine (a vasoconstrictor), or to nitroglycerin (a nitrovasodilator). By contrast, NO-dependent relaxations were attenuated in vessels harvested from

5 hypercholesterolemic animals with a reduction in the maximal response to acetylcholine. In comparison, vessels harvested from hypercholesterolemic animals receiving L-arginine supplementation had improved NO-dependent relaxation to acetylcholine. In a separate study, the

10 effect of chronic arginine supplementation to improve NO-dependent relaxation was confirmed in the hypercholesterolemic rabbit abdominal aorta.

Histomorphometric studies (planimetry of EVG-stained sections): A blinded histomorphometric analysis revealed that medial cross-sectional areas of thoracic aortae were not different between the groups. By contrast, the intimal cross-sectional area (i.e. amount of atherosclerotic plaque) of vessels from

15 hypercholesterolemic animals receiving L-arginine supplementation was reduced in comparison to those from animals receiving cholesterol diet alone. In the Arg animals the reduction in the intimal lesion was most pronounced in the ascending thoracic aorta and left main

20 coronary artery. In the left main coronary artery of hypercholesterolemic animals receiving arginine, essentially no atherosclerotic plaque developed.

25

Changes in lesion surface area: In a second series of studies, the extent of the thoracic aorta involved by

30 lesions was examined. In hypercholesterolemic rabbits receiving vehicle (n=6) or L-arginine supplement (n=6), thoracic aortae (from left subclavian artery to diaphragm) were harvested after ten weeks of treatment, bisected longitudinally, and stained with oil-red O. Vessels were

35 photographed and vessel and lesion surface area determined by planimetry. Approximately 40% of the total surface

area was covered with plaque in thoracic aortae from hypercholesterolemic animals receiving vehicle, whereas in thoracic aortae from arginine-treated hypercholesterolemic animals, less than 10% of the surface area was covered 5 with plaque (Figure 1).

To summarize, dietary arginine supplementation increases plasma arginine levels, but does not alter serum cholesterol. This is associated with significant improvement in NO-dependent vasodilation as judged by 10 bioassay. Finally, the improvement in NO-dependent vasodilation is associated with reduction in thickness and area of the lesions in vessels from hypercholesterolemic animals.

15 Example 2. Inhibition of platelet aggregation by oral L-arginine: The effect of L-arginine supplementation on platelet reactivity in rabbits that had normal chow (Control; n = 6), a 1% cholesterol diet (Chol; n = 5), or a 1% cholesterol diet supplemented with oral arginine 20 (Arg; n = 6), as detailed above, was examined. Arterial blood obtained after central ear artery cannulation was anticoagulated with 13mM sodium citrate. Platelet-rich suspension was prepared by washing platelets in calcium-free Krebs-Henseleit solution and resuspending them in 25 Tyrode's solution with albumin. Aggregation was initiated by addition of adenosine diphosphate and monitored by standard nephelometric techniques. In platelets derived from Chol animals, aggregation was not different in rate or maximum extent in comparison to platelets from Control 30 animals (A, in Figure 2). By contrast, aggregation of platelets from Arg animals was reduced by 50% (B, in Figure 2).

This reduction in platelet aggregation was associated with a two-fold greater cGMP content in aggregated 35 platelets from arginine-treated animals. The reduction of platelet reactivity could be reversed by administration of

N-methylarginine (10^{-4} M) in vitro (C, in Figure 2). Therefore, the anti-platelet effect of chronic oral arginine administration can be credited to an increased synthesis of endogenous NO. Furthermore, NO synthesis may 5 be induced in both the platelets and the endothelium.

Example 3. Inhibition of monocyte adherence:

A. Functional Binding Assay: To determine if oral arginine supplementation affects monocyte adherence, blood 10 was collected from rabbits fed normal chow (=6) a 1% cholesterol diet (=6), or a 1% cholesterol diet supplemented with L-arginine (=6), as described above. Mononuclear cells were purified from blood by Ficoll-paque density gradient centrifugation. In these preliminary 15 studies, adhesion was examined of blood leukocytes to a transformed endothelial cell line, bEnd3 (mouse brain-derived polyoma middle T antigen transformed endothelial cells). The Bend3 cells display the morphology of endothelial cells, and like human endothelial cells are 20 capable of uptake of acetylated low-density lipoprotein and express adhesion molecules in a cytokine-regulatable fashion. Cultured cells were grown to confluence in 0.5 cm² Lab-Tek chamber slides (MilesScientific) and treated with control medium or with LPS (1 mg/ml) or TNF α (25 25 U/ml) for 18 hours. Cultures were washed with fresh assay buffer, and low, medium, or high concentrations of leukocytes (0.75, 1.5, or 3×10^5 cells/ml, respectively) were added per well. Following a 30-minute incubation on a rocking platform at room temperature to allow binding, 30 the slides were inverted and immersed in buffer containing 2% (v/v) glutaraldehyde, such that non-adherent cells were lost and adherent cells were fixed to the monolayer. The adherent mononuclear cells were enumerated using video-light microscopy.

35 Monocytes from hypercholesterolemic animals (Chol) exhibited greater adherence, consistent with observation

by others, that monocytes from hypercholesterolemic cats or humans exhibit greater adherence to cultured endothelial cells. (deGruijter et al. (1991) *Metabol. Clin. Exp.* 40:1119-1121; Fan et al. (1991) *Virchows Arch.* 5 *B Cell Pathol.* 61:19-27).

In comparison to monocytes derived from vehicle-treated hypercholesterolemic animals (Chol), those from arginine-treated hypercholesterolemic animals (Arg) were much less adherent. This data shows that the arginine 10 treatment inhibits adhesion of monocytes to the endothelium, which is the first observable event in atherogenesis.

Example 4. Dietary L-Arginine Inhibits the Enhanced 15 Endothelial-Monocyte Interaction In Hypercholesterolemia

The earliest observable abnormality of the vessel wall in hypercholesterolemic animals is enhanced monocyte adherence to the endothelium, which occurs within one week of a high cholesterol diet. This event is thought to be 20 mediated by the surface expression of endothelial adhesion molecules and chemotactic proteins induced by hypercholesterolemia.

Another endothelial alteration that occurs in parallel is a reduced activity of nitric oxide (i.e., NO), 25 derived from metabolism of L-arginine. As shown above chronic dietary supplementation with L-arginine restores NO-dependent vasodilatation in hypercholesterolemic rabbits, and that this improvement in NO activity is associated with a striking anti-atherogenic effect. In 30 the following study was tested the hypothesis that the anti-atherogenic effect of dietary arginine was mediated by endothelial derived NO which inhibits monocyte-endothelial cell interaction.

Methods. **Animals.** Male New Zealand White rabbits 35 were pair fed, receiving one of the following dietary interventions for two weeks: normal rabbit chow (Cont,

n=7); rabbit chow enriched with 1% cholesterol (Chol, n=7); or 1% cholesterol chow supplemented with 2.25% L-arginine HCl in the drinking water (Arg, n=7) *ad libitum* throughout the course of the study. In a second series of 5 studies designed to further explore the role of endogenous NO on monocyte-endothelial cell interaction, another group of animals were pair fed, receiving a normal rabbit diet supplemented with either vehicle control (N=5) or the NO synthase antagonist, nitro-L-arginine (L-NA, 10 mg/100 ml; 10 n=5), administered in the drinking water *ad libitum* throughout the course of the study (for an average daily dose of 13.5 mg/kg/day). In a third series of experiments animals received a normal diet and either vehicle (n=4), L-NA (13.5 mg/kg/day; n=4), or L-NA and hydralazine (n=4) 15 added to the drinking water for two weeks. At this dose, hydralazine (5 mg/kg/day) reversed the increase in blood pressure induced by L-NA. One day before sacrifice (after 2 weeks of dietary intervention), animals were lightly sedated and the central ear artery was cannulated for 20 collection of blood samples.

Mononuclear cell culture and isolation. Murine monocyteoid cells, WEHI 78/24 cells were grown in Dulbecco's Modified Eagle's Medium supplemented 10% fetal calf serum (vol/vol) and were kept in an atmosphere of 5% 25 CO₂/95% air. Prior to binding studies, mononuclear cells were fluorescently labeled with TRITC (3 µg/ml). To confirm the results using WEHI cells, in some studies binding studies were performed in parallel using rabbit mononuclear cells. Mononuclear cells were isolated from 30 fresh whole blood of Control rabbits before sacrifice.

Preparation of aortic endothelium and binding assay. After 2 weeks of the dietary intervention, the thoracic aortae were removed and placed in cold, oxygenated saline. A 15 mm segment of thoracic aorta was excised from a point 35 immediately distal to the left subclavian artery to the mid-thoracic aorta. The segments were then carefully

opened longitudinally and placed into culture dishes containing HBSS medium. Aortic strips were fixed to the culture dish using 25 gauge needles so as to expose the endothelial surface to the medium. Culture dishes were 5 then placed on a rocking platform at room temperature.

After 10 minutes the HBSS medium was replaced by binding medium containing WEHI cells. The aortic strips were incubated with the mononuclear cells for 30 minutes. The medium was then replaced by fresh binding medium 10 without cells to remove non-adherent cells. The aortic segments were then removed and placed on a glass slide, and adherent cells counted under epifluorescent microscopy from at least 30 sites on each segment.

Results. Monocyte adhesion to rabbit aortic 15 endothelium. Exposure of WEHI 78/24 cells to normal rabbit aortic endothelium results in a minimal cell binding in this *ex vivo* adhesion assay. However, when WEHI cells were incubated with aortic endothelium from hypercholesterolemic animals (Chol; n=7), cell binding 20 was enhanced 3-fold in comparison to Cont (n=7). The increased cell binding manifested by aortic endothelium of hypercholesterolemic animals was significantly attenuated by L-arginine supplementation (n=7). (Figure 3) Similar results were achieved when adhesion assays were performed 25 in parallel with mononuclear cells that were freshly isolated from Cont animals (n=2) in each of the three groups.

Effect of chronic NO synthase inhibition on 30 endothelial adhesiveness. To further investigate the role of endothelium-derived NO in modulating endothelial-monocyte interaction, an additional series of binding studies were performed using thoracic aorta from animals that received regular chow supplemented with vehicle (n=5) or the NO synthase inhibitor, L-NA (n=5). The adhesion of 35 WEHI cells was markedly increased when incubated with aortic endothelium from L-NA animals compared to control

endothelium. This effect could not be attributed to hypertension caused by L-NA since concomitant administration of hydralazine normalized blood pressure but did not reverse the augmentation of cell binding 5 induced by L-NA.

In a separate series of studies it was confirmed that chronic administration of L-NA (the inhibitor of NO synthase) significantly inhibited generation and release of NO from the vessel wall (as measured by 10 chemiluminescence), compared to vessels from animals treated with vehicle or arginine.

The salient findings of this investigation are: 1) monocyte binding to the endothelium *ex vivo* is increased in vessels from hypercholesterolemic animals; 2) this 15 increase in monocyte binding is attenuated in hypercholesterolemic animals treated chronically with the NO precursor L-arginine; 3) monocyte binding to the endothelium is increased in vessels from normocholesterolemic animals treated with the NO synthase 20 antagonist L-nitro-arginine; and 4) this effect of NO synthase antagonism was not reversed by administration of hydralazine in doses sufficient to normalize blood pressure. These findings are consistent with the hypothesis that NO inhibits monocyte-endothelial cell 25 interaction.

To conclude, an *ex vivo* model of monocyte binding has been used to study the increase in endothelial adhesiveness induced by hypercholesterolemia. Endothelial adhesiveness is attenuated by oral administration of the 30 NO precursor L-arginine is shown. Conversely, inhibition of NO synthase activity by oral administration of nitro-arginine strikingly increases endothelial affinity for monocytes *ex vivo*. The data are consistent with NO being an endogenous anti-atherogenic molecule.

Example 5. Oral Arginine causes regression of atherosclerosis in hypercholesterolemic rabbits: Our previous work demonstrated that oral arginine could prevent the development of plaque in hypercholesterolemic animals but it was not known if pre-existing plaque could be affected by arginine treatment. This is clinically important if arginine is to be useful in the treatment of pre-existing atherosclerosis in humans. Accordingly, New Zealand white rabbits (n=85) received normal chow or 0.5% cholesterol chow for 10 weeks. Subsequently, half of the hypercholesterolemic rabbits were given 2.25% (W/V) L-arginine in their drinking water. Thoracic aortae were harvested at weeks 10, 14, 18, or 23. Rings of aorta were used to assess NO-dependent vasodilation to acetylcholine (ACh). Maximal relaxation to ACh in the hypercholesterolemic rabbits receiving vehicle (CHOL) became progressively attenuated from 53.4% (at week 10) to 17.4% (by week 23). Planimetry of the luminal surface of the aortae from CHOL animals revealed a progressive increase in plaque area from 30.3% (at week 10) to 56.5% (by week 23) of the total surface of the thoracic aorta. By contrast, hypercholesterolemic animals receiving arginine (ARG) manifested improved endothelium-dependent relaxation associated with a reduction of plaque area at 14 and 18 weeks. Lesion surface area in all arginine treated hypercholesterolemic animals (weeks 14-23) was significantly reduced in comparison to vehicle-treated hypercholesterolemic animals (Figure 4). The arginine-induced improvement in endothelium-dependent relaxation was associated with an increased generation of vascular NO, and a reduced generation of vascular superoxide anion. By 23 weeks, 3 of 7 ARG animals had persistent improvement in NO-dependent vasodilation and exhibited a further reduction of plaque area to 5.4%.

35 **Conclusions:** hypercholesterolemia induces a progressive loss of NO-dependent vasodilation associated

with progressive intimal lesion formation. Administration of L-arginine to animals with pre-existing intimal lesions augments vascular NO elaboration, reduces superoxide anion generation, and is associated with a reduction in plaque 5 area. This is the first demonstration that restoration of NO activity can induce regression of pre-existing intimal lesions, and provides evidence that L-arginine therapy may be of potential clinical benefit.

10 **Example 6. Oral arginine administration restores vascular NO activity and inhibits myointimal hyperplasia after balloon injury in hypercholesterolemic rabbits.**

Purpose. The purpose of this study was to determine if the alterations in vascular function and structure 15 following balloon angioplasty in hypercholesterolemic rabbits could be inhibited by restoration of endogenous nitric oxide (NO) activity.

Methods. Twenty-eight New Zealand white rabbits were randomized into one of three dietary groups and received 20 either normal rabbit chow, 0.5% cholesterol diet, or 0.5% cholesterol diet plus L-arginine hydrochloride (2.25% W/V) in the drinking water. After six weeks of dietary intervention, the left iliac artery of each animal was subjected to a balloon angioplasty. Four weeks later, the 25 iliac arteries were harvested for vascular reactivity studies and immunohistochemistry.

Results. The bioassay studies indicated that 30 endothelium-derived NO activity was inhibited in hypercholesterolemic animals in comparison to normocholesterolemic animals. The administration of arginine partially restored endothelium-derived NO activity. Balloon angioplasty induced intimal thickening which was largely composed of vascular smooth muscle cells and extracellular matrix. In the setting of 35 hypercholesterolemia, vascular injury induced an exuberant myointimal lesion that was augmented by the accumulation

of lipid-laden macrophages. Administration of L-arginine induced a quantitative as well as qualitative change in the lesion. Dietary arginine reduced intimal thickening in the injured vessels of hypercholesterolemic animals, 5 and substantially inhibited the accumulation of macrophages in the lesion (Figure 5).

Conclusions. We report that the lesions induced by balloon angioplasty in hypercholesterolemic animals are markedly reduced by oral administration of arginine. 10 Moreover, we find that the nature of the lesion is altered, with a striking reduction in the percentage of macrophages comprising the lesion. Hypercholesterolemia induces an endothelial vasodilator dysfunction in the rabbit iliac artery that is reversible by chronic oral 15 administration of arginine.

Example 7. Nitric oxide regulates monocyte chemotactic protein-1. Our previous studies had established that oral arginine administration could 20 enhance vascular NO synthesis. This increase in vascular NO synthesis was associated with inhibition of monocyte adherence and accumulation in the vessel wall (thereby reducing the progression, and even inducing regression, of plaque). The question remained: "How does vascular nitric 25 oxide inhibit monocyte adherence and accumulation in the vessel wall?"

Monocyte chemotactic protein-1 (MCP-1) is a 76-amino acid chemokine thought to be the major chemotactic factor for monocytes (chemotactic factors are proteins that 30 attract white blood cells). We hypothesized that the anti-atherogenic effect of NO may be due in part to its inhibition of MCP-1 expression.

Methods and Results. Smooth muscle cells (SMC) were isolated from normal rabbit aortae by explant method. 35 Cells were then exposed to oxidized LDL (30 µg/ml) (which is known to induce vascular cells to synthesize MCP-1).

The expression of MCP-1 in SMC was associated with an increased generation of superoxide anion by the SMC, and increased activity of the transcriptional protein NF κ B. All of these effects of oxidized LDL cholesterol were 5 reduced by previous exposure of the SMC to the NO-donor DETA-NONOate (100 μ M) ($p<0.05$). To determine if NO exerted its effect at a transcriptional level, SMC and COS cells were transfected with a 400 bp fragment of the MCP-1 promoter. Enhanced promoter activity by oxLDL was 10 inhibited by DETA-NO.

To investigate the role of endogenous NO in the regulation of MCP-1 *in vivo*, NZW rabbits were fed normal chow, normal chow plus nitro-L-arginine (L-NA) (to inhibit vascular NO synthesis), high cholesterol diet (Chol), or 15 high cholesterol diet supplemented with L-arginine (Arg) (to enhance NO synthesis). After two weeks, thoracic aortae were harvested and total RNA was isolated. Northern analysis demonstrated increased expression of MCP-1 in Chol and L-NA aortae; this expression was 20 decreased in aortae from Arg animals. These studies indicate that the anti-atherogenic effect of NO may be mediated in part by its inhibition of MCP-1 expression. NO inhibits the generation of superoxide anion by the vascular cells and thereby turns off an oxidant-responsive 25 transcriptional pathway (i.e. NF κ B-mediated transcription) activating MCP-1 expression.

Example 8. Nitric Oxide inhibits the expression of an endothelial adhesion molecule known to be involved in atherosclerosis.

Vascular cell adhesion molecule (VCAM-1) is an endothelial adhesion molecule that binds monocytes. This molecule is expressed by the endothelium of hypercholesterolemic animals, and is expressed by endothelial cells overlying plaque in animals and humans. This adhesion molecule is believed to participate in monocyte adherence and accumulation in the vessel wall during the development of plaque. Other workers have shown that the expression of this molecule is regulated by an oxidant-responsive transcriptional pathway mediated by the transcriptional factor NF κ B. Endothelial cells exposed to oxidized LDL cholesterol (or cytokines like TNF- α) begin to generate superoxide anion. Superoxide anion turns on oxidant-responsive transcription leading to the expression of VCAM-1 and MCP-1 (and probably other genes that participate in atherosclerosis). Our data indicates that NO inhibits the generation of superoxide anion, thereby turning off these oxidant-responsive transcriptional pathways.

Methods and Results: Confluent monolayers of human aortic endothelial cells (HAEC) were exposed to static or fluid flow conditions for 4 hours (fluid flow stimulates the production of endogenous nitric oxide). Medium was then replaced and cells were then incubated with native LDL (50 μ g/ml), oxidized LDL (30 μ g/ml), or LPS (10 ng/ml) + TNF- α (10 U/ml) for an additional 4 hours. Functional binding assays utilizing THP-1 monocytes were then performed. Superoxide production by HAECs was monitored by lucigenin chemiluminescence and expression of the adhesion molecules VCAM-1 and ICAM-1 was quantitated by flow cytometry. Whereas native LDL had little effect, incubation with either oxLDL or LPS/TNF significantly increased superoxide production, NF- κ B activity, VCAM-1

expression and endothelial adhesiveness for monocytes. Previous exposure to fluid flow inhibited endothelial adhesiveness for monocytes (Figure 6) and the other sequelae of exposure to cytokines or oxidized lipoprotein.

5 The effect of fluid flow was due to shear-induced release of nitric oxide since coincubation with L-nitro-arginine completely abolished these effects of flow. Furthermore, the NO donor PAPA-NONOate mimicked the effects of flow.

Conclusions. Previous exposure to fluid flow

10 decreased cytokine or lipoprotein-stimulated endothelial cell superoxide production, VCAM-1 expression and monocyte binding; the effects of flow are due at least in part to nitric oxide. NO participates in the regulation of the endothelial generation of superoxide anion and thereby

15 inhibits oxidant-responsive transcription of genes (i.e. VCAM-1 and MCP-1) that are involved in atherogenesis.

Example 9. Transfection of the gene encoding NO synthase increases NO generation and inhibits monocyte 20 adherence.

The following experiment was done to determine if transfer of the gene encoding NO synthase (the enzyme that produces NO) could increase generation of nitric oxide and thereby inhibit monocyte adherence. Cultured endothelial

25 cells (bEnd-3; a murine endothelial cell line) were transfected with a plasmid construct encoding the NO synthase gene, using lipofectamine liposomal technique. Forty-eight hours later, generation of nitric oxide was measured using chemiluminescence. Nitric oxide generation

30 was increased 2-fold in cells transfected with the NO synthase construct (but not in cells transfected with a control construct). In parallel, binding assays were performed using a murine monocyteoid cell line. The binding of monocyteoid cells to the endothelial cells was

35 reduced by 30% in those cells transfected with the NO synthase construct.

Conclusion: endothelial cells transfected with a plasmid construct containing the NO synthase gene were able to elaborate more nitric oxide. The increased elaboration of nitric oxide was associated with an 5 inhibition of monocyte binding to the endothelial cells.

Example 10. Effect of NO synthase expression on proliferation of vascular smooth muscle cells: Cultured rat aortic vascular smooth muscle cells under confluent 10 quiescent conditions were studied. An efficient viral coat protein-mediated DNA transfer method was employed to transfect the cells with the NO synthase gene driven by the β -actin promoter and CMV enhancer. This resulted in increased NO synthase activity (as measured by the 15 arginine-to-citrulline conversion assay) in comparison to control vector transfected cells. Transfection of the NO synthase gene completely abolished serum-stimulated DNA synthesis compared to control vector transfection. These 20 results indicated that increased expression of NO synthase (associated with increased production of NO) inhibits excessive proliferation of vascular smooth muscle cells. This inhibition can be correlated with treatment of atherosclerosis and restenosis.

25 Example 11. Gene Therapy Using NO Synthase cDNA Prevents Restenosis

The study above indicated that NO inhibits proliferation of vascular smooth muscle cells. In atherosclerosis and restenosis, excessive proliferation of 30 vascular smooth muscle cells contributes to lesion formation. Injury to the endothelium in atherosclerosis and after catheter interventions apparently reduces or removes the salutary influence of NO. The following study shows delivery of the gene for NO synthase to the vessel 35 wall inhibits lesion formation.

A plasmid construct encoding the cDNA of endothelial-type NO synthase (EC-NOS) was synthesized. A full length cDNA encoding for EC-NOS was inserted into the EcoRI site of the pUCCaggs expression vector. Balloon angioplasties 5 of the carotid artery in Sprague-Dawley rats were performed and HVJ-liposomes with plasmids encoding EC-NOS cDNA infused, or plasmids lacking EC-NOS cDNA (control vector) infused. After 4 days to 2 weeks, the rats were sacrificed and the carotid arteries harvested for: 1) 10 histomorphometry; 2) measurement of DNA synthesis; and 3) ex vivo determination of NO synthesis and release by bioassay and by chemiluminescence.

Results. Morphometric measurements 2 weeks after injury revealed a significant (68%) reduction of intimal 15 lesion thickness in EC-NOS treated (Inj + NOS) in comparison to control vector treated (Inj + CV) or untreated (Inj) injured vessels. (Figure 7) Measurements of DNA synthesis were performed four days after injury using bromodeoxyuridine. EC-NOS transfection 20 significantly limited bromodeoxyuridine incorporation (by 25%) in comparison to control vector treated or untreated injured vessels. Vessel segments were studied ex vivo using organ chamber technique to bioassay for NO release. Calcium ionophore increases intracellular calcium and 25 activates NO synthase to produce NO. Calcium ionophore induced relaxations in injured carotid arteries transfected with control vector that were only 15% of uninjured vessels. Injured arteries that had been transfected with EC-NOS relaxed to a much greater degree, 30 approximately 50% of that observed in uninjured vessels. Direct measurement of NO (by chemiluminescence) released into the medium revealed that NO released by injured tissues (transfected with the control vector) was only 20% of that released by normal uninjured tissues. By 35 contrast, injured tissues transfected with EC-NOS released more NO (about 75% of normal).

To conclude, balloon angioplasty of the rat carotid artery removes the endothelial source of NO, induces excessive vascular smooth muscle DNA synthesis and proliferation, resulting in an intimal lesion 5 (restenosis). Transfection of the vessel with EC-NOS at the time of balloon injury partially restores NO production by the vessel, and this is associated with reduced DNA synthesis and vascular smooth muscle proliferation, thereby reducing lesion formation. These 10 results are consistent with the conclusion that NO is an endogenous anti-atherogenic molecule.

Example 12. Local application of L-arginine to the vessel wall inhibits myointimal hyperplasia:

15 The previous studies revealed that oral administration of arginine could enhance vascular NO activity and inhibit lesion formation induced by a high cholesterol diet and/or vascular injury (with balloon angioplasty). To determine if intraluminal application of 20 arginine to the vessel wall at the time of balloon angioplasty could inhibit lesion formation, the following study was performed. Rabbits (n=7) were fed a 1% cholesterol diet. After one week, angioplasty of the 25 iliac arteries was performed. After angioplasty of one iliac artery, a local infusion catheter was used to expose the injured area to a high concentration of arginine (6 mM). The other iliac artery was subjected to balloon angioplasty, but not treated with a local infusion. After 30 four weeks, the vessels were harvested, and segments of the arteries processed for histomorphometry. Initial thickening in the arginine-treated vessels was significantly reduced (Figure 8). This study indicates that the local intraluminal application of high doses of 35 arginine can reduce myointimal hyperplasia after vascular injury.

Example 13. Exclusion of the Effect of Enhanced Nitrogen or Caloric Balance as Causing the Observed Results.

To exclude an effect of L-arginine on nitrogen or 5 caloric balance as the cause of these results, six animals received 1% cholesterol diet supplemented by additional methionine to increase the dietary methionine six-fold. At ten weeks animals were sacrificed for studies of platelet and vascular reactivity, and histomorphometry. 10 Endothelium-dependent relaxation, platelet aggregation and intimal thickness were not different from those of animals fed 1% cholesterol diet alone. These results reveal that another amino acid, methionine (which is not a precursor of NO) does not mimic the effect of the amino acid 15 L-arginine. Therefore it seems likely that the effect of L-arginine is due to its metabolism to nitric oxide, rather than some other effect of amino acid administration (i.e. change in nitrogen or caloric balance).

20 **Example 14. L-lysine enhances vascular NO activity and inhibits atherogenesis.**

L-lysine is a basic amino acid like L-arginine, but is not known to be metabolized by NO synthase to NO. Therefore, the following results were unexpected. New 25 Zealand white rabbits were fed a normal or high cholesterol chow (n=18). Half of the animals on the cholesterol diet also received oral L-lysine. After ten weeks, the thoracic aortae were harvested and bioassayed for vascular NO synthesis, and histomorphometry to assess 30 lesion formation was performed as described above. The administration of L-lysine was just as effective as L-arginine to increase vascular NO activity in the hypercholesterolemic animals as assessed by endothelium-dependent vasorelaxation. (Figure 9) The improvement in 35 vascular NO activity was associated with a marked reduction in vascular lesion formation.

This study revealed the unexpected result that L-lysine can enhance vascular NO activity and inhibit atherosclerosis.

5 Example 15. Oral L-arginine normalizes monocyte adhesiveness in hypercholesterolemic humans

Adherence of monocytes to the endothelium is the first observable event in the development of atherosclerosis. We hypothesized that chronic oral 10 administration of L-arginine to hypercholesterolemic humans would enhance the generation of endothelium-derived NO, and thereby inhibit the interaction of monocytes with the endothelium. In this investigation we have developed a reproducible assay for the binding of human monocytes to 15 cultured endothelial cells, and we have examined the effect of hypercholesterolemia and L-arginine treatment on this interaction.

The control subject population in this study included 12 normal volunteers, (10 males and 2 females), with an 20 average age of 37 ± 2 yrs. Normalcy was determined by a careful history, physical examination, and laboratory analysis to exclude individuals with hematologic, renal, or hepatic dysfunction or clinically evident atherosclerosis. There were 20 patients (10 males and 10 25 females) with hypercholesterolemia as defined by a total plasma cholesterol greater than 240 mg/dl and a LDL cholesterol level greater than 160 mg/dl. These individuals had an average age of 51 ± 2 yrs. None of the subjects were taking diuretics, vasoactive 30 medications, antiplatelet or hypolipidemic medications. This study was approved by the Stanford University Administrative Panel on Human Subjects in Medical Research and each subject gave written informed consent before entry into the study. Blood was drawn from each subject 35 in the postabsorptive state.

We isolated human monocytes from citrated venous blood. The blood was centrifuged and the buffy coat removed and resuspended with HBSS. The suspension was then carefully layered onto a cushion of 1.068-d 5 Histopaque, and centrifuged. After centrifugation, the monocytes were aspirated.

We used the transformed endothelial cell (EC) line, bEnd3 to examine monocyte-endothelial binding *ex vivo*. The bEnd3 cells express endothelial adhesion molecules and 10 bind monocytes in a cytokine-inducible fashion with kinetics similar to those observed with human umbilical vein endothelium. Monocytes were added to the wells containing the endothelial monolayers to reach a final cell number of $3 \times 10^6/\text{ml}$. In some studies, monocytes 15 were exposed *in vitro* for 30 minutes to sodium nitroprusside (an NO donor) prior to the binding assay.

The six-well plates were transferred to a rocking platform and rocked for 30 minutes at room temperature. After 30 minutes, the cell suspension was aspirated from 20 each well and wells were then rinsed with binding buffer to remove non-adherent monocytes. Videomicroscopic counting of adherent cells was performed using a computer aided image analysis system.

Results. Oral administration of L-arginine (7 g 25 daily for 2 weeks) to hypercholesterolemic humans increased plasma arginine values by 60% (from 79 ± 10 to 128 ± 12 mM; n=7), whereas L-arginine values in the placebo-treated (n=3) and normocholesterolemic (n=6) groups remained unchanged. The administration of oral L-arginine 30 had no effect on any of the biochemical or hematologic parameters and was well tolerated. Oral L-arginine did not lower total cholesterol or LDL cholesterol. Two patients dropped out of the study; one because he did not want to take the pills, and one because of reactivation of 35 oral herpes during the study.

The results of the adhesion assays were highly reproducible. Monocytes derived from hypercholesterolemic individuals demonstrated a $50\pm 8\%$ increase in bound cells/hpf in comparison to cells from normal individuals 5 ($p<0.0001$). The degree of adhesiveness was correlated to the plasma levels of LDL cholesterol ($R=0.7$, $n=33$; $p<0.0001$; Figure 10).

In an open-label study, 3 hypercholesterolemic individuals were treated with oral L-arginine 10 supplementation for 2 weeks. Arginine treatment resulted in a 38% decrease in monocyte adhesiveness.

To confirm this effect of L-arginine treatment and to control for any experimental bias, a double-blinded, placebo-controlled, randomized study was performed. Ten 15 hypercholesterolemic subjects were randomized (1:2) to placebo or L-arginine treatment; 6 normocholesterolemic individuals were studied in parallel to control for variation over time in the binding assay. At baseline, the adhesion of monocytes from both hypercholesterolemic 20 groups was increased in comparison to the normocholesterolemic individuals ($p<0.001$). After 2 weeks of L-arginine administration, there was an absolute reduction of 53% in monocyte binding ($n=7$, $p<0.005$, baseline vs 2 weeks) (Figure 11). By contrast, there was 25 no significant change in the adhesiveness of monocytes isolated from hypercholesterolemic individuals treated with placebo. Two weeks after discontinuation of the L-arginine treatment, the adhesiveness of the monocytes isolated from hypercholesterolemic individuals had 30 significantly increased compared to the normocholesterolemic individuals ($34\pm 9\%$ increase in bound cells/hpf; $p<0.05$), and was also significantly increased in comparison to the binding obtained after 2 weeks of L-arginine therapy (an increase of $30\pm 9\%$, $p<0.05$). The 35 adhesiveness of monocytes from placebo-treated

hypercholesterolemic individuals did not change significantly during the washout period.

In some studies monocytes were exposed to sodium nitroprusside or vehicle control for 30 minutes *in vitro*.

5 Pre-incubation of the cells from hypercholesterolemic individuals with the NO donor sodium nitroprusside (10^{-5} M) markedly reduced binding ($164 \pm 9\%$ vs $98 \pm 7\%$ vehicle vs sodium nitroprusside; $n=7$, $p<0.0005$; values expressed as a percent of the normocholesterolemic control exposed to 10 vehicle; Figure 12).

To conclude, the salient findings of this investigation are that: 1) Hypercholesterolemia enhances the adhesiveness of monocytes for endothelial cells, 2) oral arginine supplementation reverses the increase in 15 adhesiveness of monocytes from hypercholesterolemic individuals, and 3) the effect of oral arginine is mimicked *in vitro* by exposure of the monocytes from hypercholesterolemic individuals to sodium nitroprusside, an NO donor.

20

Example 16. Platelet Hyperaggregability in Hypercholesterolemic Humans: Reversal by Oral L-Arginine

In this study we tested the hypothesis that chronic L-arginine supplementation would inhibit platelet 25 reactivity in hypercholesterolemic humans. Venous blood was collected from normal (NC; $n=11$) and hypercholesterolemic (HC; $n=22$) volunteers for isolation of platelet-rich plasma and aggregometry. Half the HC group received L-arginine (7 g/d) for 2 weeks; 30 aggregometry was performed using collagen (5 mg/ml) before and after two weeks of treatment.

Results: HC platelets were hyperaggregable. After two weeks of L-arginine, the aggregability of HC platelets was reduced (Figure 13). These studies are consistent 35 with our previous observations in animals that oral administration of L-arginine inhibits platelet reactivity.

Example 17. Intravenous Administration of L-Arginine Improves Endothelium-dependent Vasodilation in Hypercholesterolemic Humans:

Hyperlipoproteinemia impairs endothelium-dependent 5 vasodilation, even before the development of atherosclerosis. We hypothesized that administration of L-arginine may increase synthesis of NO and thereby improve endothelium-dependent vasodilation in hypercholesterolemia. Indeed, our earlier studies 10 conducted in cholesterol-fed rabbits support this notion. The following data demonstrates that L-arginine augments endothelium-dependent vasodilation in forearm resistance vessels of hypercholesterolemic humans.

The control subject population in this study included 15 11 normal volunteers comprising (10 males and 1 female). Their ages ranged from 31 to 49 and averaged 39 ± 2 yr. There were 14 patients with hypercholesterolemia. Hypercholesterolemia was defined as a serum LDL 20 cholesterol level greater than the 75th percentile adjusted for age and sex. These individuals included 11 males and 3 females whose ages ranged from 22 to 48 and averaged 38 ± 2 years.

Under local anesthesia and sterile conditions, a 25 polyethylene catheter was inserted into a brachial artery of each subject for determination of blood pressure and for infusion of drugs. A separate polyethylene catheter was inserted into the antecubital vein for infusion of L-arginine. Bilateral forearm blood flow was determined by 30 venous occlusion strain gauge plethysmography, using calibrated mercury-in-silastic strain gauges, and expressed as ml/100 ml tissue per min.

To assess NO-dependent vasodilation, methacholine chloride (which induces the endothelium to release NO) was administered via the brachial artery. Forearm blood flow 35 was measured during infusion of methacholine chloride at concentrations of 0.3, 3, and 10 μ g/min each for 3 min.

After completion of the methacholine chloride infusions, all normal subjects and 10 individuals with hypercholesterolemia were given L-arginine intravenously over 30 minutes and then the methacholine infusions were 5 repeated. D-arginine, the enantiomer of L-arginine, is not a precursor of NO. Thus, to ensure that any observed effects of L-arginine were due to its contribution to the synthesis of NO and not just secondary to its physiochemical properties, five individuals with 10 hypercholesterolemia received D-arginine intravenously.

Results. Baseline blood pressure, heart rate, and forearm blood flow did not differ between normal and hypercholesterolemic subjects. Intraarterial infusion of methacholine chloride caused a dose-dependent increase in 15 forearm blood flow. In the hypercholesterolemic subjects, however, cholinergic vasodilation was less than that of normal subjects ($p<0.05$). The maximal forearm blood flow response to methacholine in normal subjects is 19.0 ± 1.9 ml/100 ml of tissue per min, and in hypercholesterolemic 20 subjects, it was 13.7 ± 1.7 ml/100 ml of tissue per min ($p<0.05$).

In the normal subjects, L-arginine did not potentiate the vasodilation that occurred during the administration of methacholine chloride. In the hypercholesterolemic 25 subjects, however, the L-arginine infusion augmented the vasodilation to methacholine chloride by 25% ($p<0.05$). There were no complications or side-effects of the L-arginine infusions.

The important findings in this study are: (a) 30 endothelium-dependent vasodilation (due to the release of NO) is reduced in forearm resistance vessels of hypercholesterolemic humans; and (b) intravenous administration of L-arginine improves endothelium-dependent vasodilation in these individuals. NO not only 35 causes vasodilation, but it also inhibits platelet

aggregation and suppresses monocyte adhesion in hypercholesterolemic humans..

Example 18. Administration of Intravenous L-Arginine
5 Improves Coronary Endothelial Function in Cardiac
Transplant Recipients

A reduction in coronary NO-dependent vasodilation occurs in cardiac transplant recipients and may represent an early marker for the development of graft 10 atherosclerosis. Reduced NO-dependent vasodilation in response to acetylcholine is an indicator of endothelial dysfunction and has been attributed to reduced synthesis or accelerated degradation of endothelium-derived nitric 15 oxide. We hypothesized that endothelial dysfunction of epicardial coronary arteries at an early stage of coronary allograft atherosclerosis might be reversed by L-arginine. The present study tested the hypothesis that administration of L-arginine, the precursor of 20 endothelium-derived NO, improves endothelial vasodilator function of coronary conduit and resistance vessels.

Cardiac transplant recipients scheduled for elective annual coronary angiography at Stanford University hospital were screened for possible participation in the study. The study protocol was approved by the Stanford 25 University Committee on Human Subjects in Medical Research. All patients gave written informed consent. Eighteen patients who had cardiac transplantation 1 to 13 years previously were studied.

Vasoactive medications were discontinued at least 12 30 hours before the study. After diagnostic angiography revealed no visually apparent coronary stenosis, a guiding catheter was used to cannulate the left main coronary artery. An infusion catheter was then advanced over a Doppler flow velocity guide wire into a nonbranching 35 segment of the coronary artery for infusion of acetylcholine (which stimulates the endothelium to release

NO). After baseline angiography was performed, increasing concentrations of acetylcholine were serially infused over 3 minutes. Infusion of acetylcholine continued until the maximum dose (10^4 mol/L) was reached or until total 5 coronary occlusion occurred. Then an intravenous infusion of L-arginine (30g over 15 minutes) was performed. Thereafter, the intracoronary infusion of acetylcholine was repeated. Coronary angiography and Doppler flow velocity recording was performed at the end of the L- 10 arginine infusion and after the infusion of each concentration of acetylcholine.

Results. In epicardial coronary arteries of these transplant recipients, acetylcholine caused vasoconstriction. Epicardial coronary vasoconstriction 15 caused by acetylcholine was attenuated by infusion of L-arginine (10^4 mol/L, -6.8% versus -2.8%; $p<.01$). In coronary resistance vessels, acetylcholine induced vasodilation, reflected by increases in blood flow. The increase in coronary blood flow was significantly enhanced 20 with L-arginine ($p<.002$; Figure 14). There were no complications or side-effects of the L-arginine infusion.

The coronary vasculature of cardiac transplant recipients exhibits a generalized reduction of NO-dependent vasodilation. L-arginine improves endothelial- 25 derived NO dependent vasodilation of both coronary microvasculature and epicardial coronary arteries.

It is evident from the above results, that by enhancing the nitric oxide levels, by means of nitric oxide precursor compounds or other compounds in the nitric 30 oxide pathway, substantial benefits will ensue to patients with vascular degenerative diseases. This treatment will restore normal vascular tone (preventing excessive vasoconstriction and elevation of blood pressure; and will improve blood flow to the heart, brain, and other critical 35 tissues thereby enhancing exercise tolerance and relieving symptoms such as angina or cerebral ischemia); and will

diminish the formation of atherosclerotic plaque and restenosis (by inhibiting adhesion of monocytes and platelets, and by reducing the proliferation of vascular smooth muscle cells). Benefits may also ensue to normal 5 individuals, because NO is critically involved in exercise-mediated vasodilation, an enhancement of NO synthesis could improve blood flow and exercise capacity even in normal individuals.

By virtue of administering to the host, based on a 10 predetermined regimen, or providing in the host a supply of a component in the synthetic pathway for production of nitric oxide, so as to maintain a mildly elevated level of nitric oxide in the host, particularly at the site to be treated, the incidence of plaque formation can be 15 substantially diminished. This can be achieved in a variety of ways: by oral administration in accordance with a predetermined regimen of various compounds associated with nitric oxide formation, e.g. L-arginine and/or L-lysine; by administration at the site, in a predetermined 20 regimen of compounds which can produce nitric oxide, either directly or as a result of physiologic action of endogenous compounds, e.g. enzymes; by employing combinations of compounds, which by their action result in the production of nitric oxide; or the like. These 25 individual administrations, can be done independently or in conjunction with a regimen of other compounds associated with the production of nitric oxide.

Alternatively, one may use genetic engineering to 30 introduce a gene associated with a component in the synthetic pathway for production of nitric oxide, e.g. nitric oxide synthase, where the enhanced production of such compounds will have the effect of driving the equilibrium to an enhanced production of nitric oxide. Thus, the subject invention provides a plurality of 35 pathways to enhance the synthesis or action of nitric oxide, or reduce the degradation of nitric oxide, thereby

increasing the effect of endogenous nitric oxide to prevent the formation of vascular lesions and to inhibit restenosis.

All publications and patent applications cited in 5 this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described 10 in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from 15 the spirit or scope of the appended claims.

WHAT IS CLAIMED IS:

1. A composition for use in a method of improving function and structure of the vascular system of a human host, said method comprising:

5 administering orally to said host in accordance with a predetermined regimen a prophylactic dose of a source of L-lysine as other than a natural food source and as a dietary supplement to enhance the level of endogenous NO in the vascular system to improve vascular function.

10

2. A composition according to Claim 1, wherein said dose comprises at least 10% by weight of L-lysine and at least 50% total weight of amino acids L-lysine and L-arginine, polypeptides comprising at least about 40 mol% 15 of said amino acids, or physiologically acceptable salt thereof.

3. A composition according to Claim 2, wherein said polypeptide is an oligopeptide of L-arginine and L-lysine.

20

4. A composition according to Claim 2, wherein said dose comprises L-arginine.

5. A composition according to Claim 4, wherein said dose is administered in a daily amount in the range of 0.5 25 to 25g per day.

6. A composition according to Claim 1, wherein said dose comprises at least one of calcium, an amino acid 30 absorption enhancing compound, a cofactor for NO synthase activity, or an antioxidant in an amount sufficient to enhance the prophylactic effect of said L-lysine.

7. A composition according to any of Claims 1-6, 35 wherein said dose is administered as a tablet, capsule, or powder.

8. A composition according to any of Claims 1-6, wherein said dosage is administered as a prepared solid food, nutritional supplement or liquid.

5

9. A physiologically acceptable formulation comprising L-lysine and L-arginine of which L-lysine is at least 10 weight %, or their physiologically acceptable salts in from about 0.5 to 25g, and at least one of 10 calcium, folate, B₆, or B₁₂, in sufficient amount to enhance the effect of said L-arginine, L-lysine or their physiologically acceptable salts on enhancing the amount of NO in a human host.

15 10. A composition for use in a method for inhibiting vascular smooth muscle cell proliferation at a site of injury in the vascular system, said method comprising:

administering at said site an effective amount of at least one of L-arginine, L-lysine or its physiologically 20 acceptable salt and not less than 10 weight % L-lysine or its physiologically acceptable salt to enhance NO production;

whereby vascular smooth muscle cell proliferation is inhibited.

25

11. A composition according to Claim 10, wherein said injury is as a result of angioplasty.

12. A composition for use in a method for reducing 30 the probability of restenosis resulting from injury caused by angioplasty or atherectomy, said method comprising:

introducing intramurally proximal to the site of said injury a nitric oxide precursor at a time and in an amount to increase the amount of nitric oxide formation of 35 the cells proximal to said injury,

whereby a reduced incidence of restenosis occurs.

13. A composition according to Claim 12, wherein said nitric oxide precursor is at least one of L-arginine, L-lysine or an oligopeptide comprising at least one of L-arginine and L-lysine.

5

14. A method according to Claim 12, wherein said time is at the time of said injury and not later than four weeks thereafter.

12.

1/15




FIG 1

2/15





FIG 2

3/15

**FIG 3**

4/15




FIG 4

5/15




FIG 5

6/15




FIG 6

7/15




FIG 7

8/15




FIG 8

9/15




FIG 9

10/15




FIG 10

11/15




FIG 11

12/15




FIG12

13/15




FIG 13

14/15




FIG 14

15/15




FIG. 15

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/17241

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A23L 1/305; A61K 31/195, 38/02
US CL : 426/648, 656; 514/20, 310, 557, 564, 565

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 426/648, 656, 657; 514/20, 310, 557, 564, 565; 530/358; 930/290

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG

search terms: arginine, lysine, polyarginine, polylysine, vascular, vasodilate, atherosclerosis, thrombosis, restenosis

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,428,070 A (COOKE ET AL) 27 June 1995(27/06/95), see entire document.	10-14
X	EP 0,546,796 A (AJINOMOTO CO., INC.) 16 June 1993 (16/06/93), see entire document.	10-14
X	US 4,920,098 A (COTTER ET AL) 24 April 1990 (24/04/90), column 4, lines 2-18, column 7, lines 1-3, Examples 1-3.	1, 6-8, 10-14
X	US 5,032,608 (DUDRICK) 16 July 1991 (16/07/91), column 13, lines 48-60.	1, 6, 8, 10-14
X, E	US 5,576,287 A (ZALOGA ET AL) 19 November 1996 (19/11/96), column 5, line 38 - column 6, line 3.	1, 6, 8, 10-14

 Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	
A	document defining the general state of the art which is not considered to be of particular relevance
E	earlier document published on or after the international filing date
L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
O	document referring to an oral disclosure, use, exhibition or other means
P	document published prior to the international filing date but later than the priority date claimed
	T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
	X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
	Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
	Z document member of the same patent family

Date of the actual completion of the international search

03 JANUARY 1997

Date of mailing of the international search report

21 JAN 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230Authorized officer
JEFFREY E. RUSSEL
Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/17241

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,278,189 A (RATH ET AL) 11 January 1994 (11/01/94), column 2, lines 14-34, column 4, lines 43-49, Tables 1-2, claims 1-15.	1, 2, 4-8, 10-14
X	US 4,029,773 A (BEIGLER ET AL) 14 June 1977 (14/06/77), abstract, column 6, lines 27-63.	1, 2, 4-6, 8-14
X	US 4,847,240 A (RYSER ET AL) 11 July 1989 (11/07/89), claims 4-6.	1-3, 8, 12-14